| Size & multiples | |||
| Market Cap | $427.4M | Enterprise Value | — |
| P/E (TTM) | — | PEG (trailing) | — |
| P/S | 60.01× | P/FCF | — |
| EV/EBITDA | — | EV/EBIT | — |
| EV/Sales | — | EV/FCF | — |
| FCF Yield | −9.82% | Buyback Yield | — |
| Owner Earnings (TTM) | -$24.0M | Owner Earnings Yield | −5.62% |
| Shareholder Yield | — | ||
| Cost of capital & EVAmethodology → | |||
| Beta (5y monthly) | 0.27 | Risk-free (assumed) | 4.00% |
| Equity risk premium (assumed) | 5.00% | Cost of Equity | 5.37% |
| After-tax Cost of Debt | — | WACC | — |
| ROIC | — | EVA Spread (ROIC−WACC) | — |
| EVA | — | ||
FCF sits 75% below owner earnings — spending above maintenance (growth capex) or absorbing working capital, so FCF understates the steady-state cash the business throws off.
Flows TTM (last 4 quarters) · EPS TTM — · revenue TTM $7.1M · FCF TTM -$42.0M
Output of a disclosed model whose assumptions may be wrong — research information, not investment advice. See the Disclaimer.
Compared against all 1054 Health Care names we cover — one sector-wide pool, so the median skews toward smaller (often unprofitable) companies. Try the Size band for a cap-matched read.
| Metric | This (FY) | Peer median | IQR (25–75) | %ile |
|---|---|---|---|---|
| FCF Yield | -9.0% | -7.9% | -35.6%–1.4% | 47 ↓weak |
| Net Margin | -240.1% | -21.2% | -325.3%–7.2% | 28 ↓weak |
| Operating Margin | -585.2% | -34.5% | -552.0%–8.0% | 25 ↓weak |
| ROE | -17.5% | -36.8% | -92.5%–4.5% | 61 ↑strong |
